184 related articles for article (PubMed ID: 21839414)
21. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
22. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
23. Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.
Thiery-Vuillemin A; Llombart-Cussac A; Chaigneau L; Villanueva C; Bazan F; Montcuquet P; Maisonnette-Escot Y; Sautiere JL; Algros MP; Pivot X
Breast; 2011 Feb; 20(1):46-9. PubMed ID: 20692157
[TBL] [Abstract][Full Text] [Related]
24. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
25. Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens.
Berger AM; Lockhart K; Agrawal S
Oncol Nurs Forum; 2009 Sep; 36(5):563-70. PubMed ID: 19726396
[TBL] [Abstract][Full Text] [Related]
26. Comparison of FACT- and EQ-5D-based utility scores in cancer.
Pickard AS; Ray S; Ganguli A; Cella D
Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
[TBL] [Abstract][Full Text] [Related]
27. Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Breast Cancer Res Treat; 2012 Sep; 135(2):335-46. PubMed ID: 22689092
[TBL] [Abstract][Full Text] [Related]
28. Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study.
Mariani G; Galli G; Cavalieri S; Valagussa P; Bianchi GV; Capri G; Cresta S; Ferrari L; Damian S; Duca M; de Braud F; Moliterni A
Breast J; 2019 Mar; 25(2):237-242. PubMed ID: 30810258
[TBL] [Abstract][Full Text] [Related]
29. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
De Laurentiis M; Cancello G; D'Agostino D; Giuliano M; Giordano A; Montagna E; Lauria R; Forestieri V; Esposito A; Silvestro L; Pennacchio R; Criscitiello C; Montanino A; Limite G; Bianco AR; De Placido S
J Clin Oncol; 2008 Jan; 26(1):44-53. PubMed ID: 18165639
[TBL] [Abstract][Full Text] [Related]
30. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
; Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K
Lancet; 2012 Feb; 379(9814):432-44. PubMed ID: 22152853
[TBL] [Abstract][Full Text] [Related]
31. Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery.
Taira N; Shimozuma K; Shiroiwa T; Ohsumi S; Kuroi K; Saji S; Saito M; Iha S; Watanabe T; Katsumata N
Breast Cancer Res Treat; 2011 Aug; 128(3):735-47. PubMed ID: 21681445
[TBL] [Abstract][Full Text] [Related]
32. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
;
Lancet; 2023 Apr; 401(10384):1277-1292. PubMed ID: 37061269
[TBL] [Abstract][Full Text] [Related]
33. [Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer].
Heinemann V
Onkologie; 2003 Dec; 26 Suppl 7():11-6. PubMed ID: 14716136
[TBL] [Abstract][Full Text] [Related]
34. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials.
Zheng R; Han S; Duan C; Chen K; You Z; Jia J; Lin S; Liang L; Liu A; Long H; Wang S
Medicine (Baltimore); 2015 May; 94(17):e803. PubMed ID: 25929935
[TBL] [Abstract][Full Text] [Related]
35. Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.
Skaltsa K; Longworth L; Ivanescu C; Phung D; Holmstrom S
Value Health; 2014 Mar; 17(2):238-44. PubMed ID: 24636382
[TBL] [Abstract][Full Text] [Related]
36. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
Iwamoto T; Hara F; Uemura Y; Mukai H; Watanabe T; Ohashi Y
Breast Cancer Res Treat; 2020 Jul; 182(2):325-332. PubMed ID: 32462261
[TBL] [Abstract][Full Text] [Related]
37. Can we abandon anthracyclines for early breast cancer patients?
Henderson IC
Oncology (Williston Park); 2011 Feb; 25(2):115-24, 127. PubMed ID: 21456382
[TBL] [Abstract][Full Text] [Related]
38. Continued value of adjuvant anthracyclines as treatment for early breast cancer.
Turner N; Biganzoli L; Di Leo A
Lancet Oncol; 2015 Jul; 16(7):e362-9. PubMed ID: 26149888
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis of adjuvant therapies for breast cancer in Iran.
Bastani P; Kiadaliri AA
Int J Technol Assess Health Care; 2012 Apr; 28(2):110-4. PubMed ID: 22559752
[TBL] [Abstract][Full Text] [Related]
40. [Recent perspectives second-line chemotherapy for breast cancer].
Fujiuchi N; Ohokubo K; Saeki T; Sasaki Y
Gan To Kagaku Ryoho; 2005 Jan; 32(1):11-4. PubMed ID: 15675574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
